33例接受术前放疗的局部高危软组织肉瘤患者近期疗效和安全性回顾性分析

doi:10.19401/j.cnki.1007-3639.2023.07.007

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (7): 693-700.doi: 10.19401/j.cnki.1007-3639.2023.07.007

33例接受术前放疗的局部高危软组织肉瘤患者近期疗效和安全性回顾性分析

王雁¹(), 苏越¹, 胡涂², 刘绮颖³, 姚伟强¹, 陈勇², 严望军², 章真¹()

1.复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系，上海市放射肿瘤学重点实验室，上海市放射治疗临床医学研究中心，上海 200032
2.复旦大学附属肿瘤医院骨与软组织外科，复旦大学上海医学院肿瘤学系，上海 200032
3.复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系，复旦大学病理研究所，上海 200032

收稿日期:2023-02-02 修回日期:2023-06-29 出版日期:2023-07-30 发布日期:2023-08-10
通信作者: 章真（ORCID: 0000-0001-7825-2679），博士，主任医师。
作者简介:王雁（ORCID: 0000-0001-8750-9341），博士，主治医师。
基金资助:
希思科-青年创新肿瘤研究基金项目(Y-Young2020-0477);上海市科学技术委员会科技计划项目(21Y21900200)

Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma

WANG Yan¹(), SU Yue¹, HU Tu², LIU Qiying³, YAO Weiqiang¹, CHEN Yong², YAN Wangjun², ZHANG Zhen¹()

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Key Laboratory of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, China
2. Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3. Department of Pathology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Institute of Pathology, Fudan University, Shanghai 200032, China

Received:2023-02-02 Revised:2023-06-29 Published:2023-07-30 Online:2023-08-10
Contact: ZHANG Zhen.

摘要/Abstract

摘要：

背景与目的：对于局部高危软组织肉瘤，单纯手术治疗常常不能获得满意效果。本研究旨在评估术前放疗联合手术用于治疗局部高危软组织肉瘤患者的近期疗效和安全性。方法：回顾性分析2021年2月—2022年6月在复旦大学附属肿瘤医院接受术前放疗的连续性患者的临床资料，包括临床特征、放疗方案、影像学资料及病理学资料等。放疗的靶区勾画采用图像融合技术，将磁共振成像（magnetic resonance imaging，MRI）图像融合至模拟定位计算机体层成像（computed tomography，CT）图像上，勾画靶区时逐层参考。所有患者均接受调强适形放疗（intensity-modulated radiotherapy，IMRT）技术制订的放疗计划。计数资料采用百分数表示。分析影像学应答（完全缓解、部分缓解、疾病稳定、疾病进展、客观缓解及疾病控制）比例、病理学应答[接近病理学完全缓解（near-pathologic complete response，near-pCR），定义为≥90%的无活性肿瘤细胞]比例及毒性反应（急性皮肤损伤和术后120 d内伤口并发症）比例。结果：共41例患者在术前接受了放疗，其中33例患者符合纳入标准：31例可进行影像学评估，28例可进行病理学评估。患者的中位年龄为53岁，30例（90.9%）患者的肿瘤组织学分级为3级。影像学分析提示，6例（19.4%）患者获得部分缓解，1例患者出现疾病进展，无人获得完全缓解，客观缓解率为19.4%，疾病控制率为96.8%。病理学分析提示，8例（28.6%）患者near-pCR；排除既往接受过化疗的患者，near-pCR率为34.8%（8/23）。33.3%（11/33）和3.0%（1/33）患者出现1和2级皮肤损伤，未发生3和4级皮肤损伤。1例（3.3%）患者出现术后120 d内的严重伤口并发症。结论：利用MRI图像融合技术和IMRT技术的术前放疗对于局部高危软组织肉瘤患者，近期疗效良好，急性毒性反应可接受。

关键词: 软组织肉瘤, 术前放疗, 磁共振成像, 调强适形放疗, 客观缓解率, 伤口并发症

Abstract:

Background and purpose: Surgery alone is not enough to get satisfied outcome for locally high-risk soft tissue sarcoma (STS). We retrospectively assessed the short-term efficacy and safety of preoperative radiotherapy followed by surgery in patients with locally high-risk STS. Methods: Data from consecutive patients treated with preoperative radiotherapy at Fudan University Shanghai Cancer Center from February 2021 to June 2022 were reviewed. The data included clinical characteristics, radiotherapy regimes, radiological images and pathology slides. The target volumes of radiotherapy were delineated on computed tomography (CT) simulation images with reference to fused magnetic resonance imaging (MRI) images slides by slides. All the patients received radiotherapy planned with intensity-modulated radiotherapy (IMRT). Counting data was presented as percentages. The rates of radiological response (complete response, partial response, stable disease, progressive disease, objective response and disease control), pathological response [near-pathologic complete response (near-pCR), defined as ≥90% non-viable tumor cells] and toxicities (acute skin toxicity and major wound complications occurring within 120 d of surgery) were analyzed. Results: Forty-one patients received radiotherapy before surgery, among them 33 patients were eligible: 31 for radiological assessment and 28 for pathological assessment. The median age was 53 years. Thirty (90.0%) cases were histologically classified as Grade 3. Six (19.4%) patients achieved partial response, and 1 patient had progressive disease after radiotherapy. None got complete response. The objective response rate was 19.4%, and the disease control rate was 96.8%. Near-pCR was found in 8 (28.6%) patients. Excluding patients receiving chemotherapy previously, the near-pCR rate was 34.8% (8/23). Grade 1 and 2 skin injuries were found on 33.3% (11/33) and 3.0% (1/33) patients. No grade 3 and 4 skin injury occurred. Major wound complications within 120 d of surgery occured in 1 (3.3%) patient. Conclusion: Preoperative radiotherapy facilitated with fused MRI images and IMRT has good short-term efficacy and tolerable acute toxicities for locally high-risk STS.

Key words: Soft tissue sarcoma, Preoperative radiotherapy, Magnetic resonance imaging, Intensity-modulated radiotherapy, Objective response rate, Wound complication

中图分类号:

R738.6

王雁, 苏越, 胡涂, 刘绮颖, 姚伟强, 陈勇, 严望军, 章真. 33例接受术前放疗的局部高危软组织肉瘤患者近期疗效和安全性回顾性分析[J]. 中国癌症杂志, 2023, 33(7): 693-700.

WANG Yan, SU Yue, HU Tu, LIU Qiying, YAO Weiqiang, CHEN Yong, YAN Wangjun, ZHANG Zhen. Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma[J]. China Oncology, 2023, 33(7): 693-700.

图/表 4

图1

表1

表2

图2

参考文献 27

[1]	VON MEHREN M, KANE J M, AGULNIK M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(7): 815-833. doi: 10.6004/jnccn.2022.0035
[2]	KAINHOFER V, SMOLLE M A, SZKANDERA J, et al. The width of resection margins influences local recurrence in soft tissue sarcoma patients[J]. Eur J Surg Oncol EJSO, 2016, 42(6): 899-906.
[3]	DAVIS A M, O'SULLIVAN B, BELL R S, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma[J]. J Clin Oncol, 2002, 20(22): 4472-4477. doi: 10.1200/JCO.2002.03.084 pmid: 12431971
[4]	SAMPATH S, SCHULTHEISS T E, HITCHCOCK Y J, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients[J]. Int J Radiat Oncol Biol Phys, 2011, 81(2): 498-505. doi: 10.1016/j.ijrobp.2010.06.034
[5]	DAVIS A, OSULLIVAN B, TURCOTTE R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma[J]. Radiother Oncol, 2005, 75(1): 48-53. doi: 10.1016/j.radonc.2004.12.020 pmid: 15948265
[6]	O’SULLIVAN B, DAVIS A M, TURCOTTE R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial[J]. Lancet, 2002, 359(9325): 2235-2241. doi: 10.1016/S0140-6736(02)09292-9 pmid: 12103287
[7]	FOLKERT M R, SINGER S, BRENNAN M F, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity[J]. J Clin Oncol, 2014, 32(29): 3236-3241. doi: 10.1200/JCO.2013.53.9452 pmid: 25185087
[8]	O’SULLIVAN B, GRIFFIN A M, DICKIE C I, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma[J]. Cancer, 2013, 119(10): 1878-1884. doi: 10.1002/cncr.27951 pmid: 23423841
[9]	LI X A, CHEN X J, ZHANG Q, et al. Margin reduction from image guided radiation therapy for soft tissue sarcoma: secondary analysis of Radiation Therapy Oncology Group 0630 results[J]. Pract Radiat Oncol, 2016, 6(4): e135-e140. doi: 10.1016/j.prro.2015.11.012 pmid: 26852173
[10]	WANG D, BOSCH W, ROBERGE D, et al. RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4): e525-e528. doi: 10.1016/j.ijrobp.2011.04.038
[11]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026 pmid: 19097774
[12]	WEISS A R, CHEN Y L, SCHARSCHMIDT T J, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2020, 21(8): 1110-1122. doi: S1470-2045(20)30325-9 pmid: 32702309
[13]	ASHLEIGH GUADAGNOLO B, BASSETT R L, MITRA D, et al. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2022, 23(12): 1547-1557. doi: 10.1016/S1470-2045(22)00638-6 pmid: 36343656
[14]	National Cancer Institute. Protocol development cancer therapy evaluation program[EB/OL]. (2017-11-27)[2023-04-28]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
[15]	COINDRE J M. Recommendations for anatamo-pathologic management of soft tissue sarcomas in the adult. Pathologists of the FNCLCC Sarcoma Group (Fédération Nationale des Centres de Lutte Contre le Cancer)[J]. Ann Pathol, 1998, 18(6): 505-511.
[16]	SBARAGLIA M, BELLAN E, DEI TOS A P. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives[J]. Pathologica, 2021, 113(2): 70-84. doi: 10.32074/1591-951X-213 pmid: 33179614
[17]	FENG X Y, LI J, LI A M, et al. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma[J]. World J Surg Oncol, 2022, 20(1): 322. doi: 10.1186/s12957-022-02781-1
[18]	HUANG Z, LI N, TANG Y, et al. Neoadjuvant radiotherapy for soft tissue sarcoma in China: a preliminary result[J]. Ann Transl Med, 2022, 10(8): 452. doi: 10.21037/atm-22-98 pmid: 35571451
[19]	CASALI P G, ABECASSIS N, ARO H T, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv51-iv67. doi: 10.1093/annonc/mdy096
[20]	GORTZAK E, AZZARELLI A, BUESA J, et al. A randomised phase Ⅱ study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma[J]. Eur J Cancer, 2001, 37(9): 1096-1103. doi: 10.1016/S0959-8049(01)00083-1
[21]	VOSS R K, CHIANG Y J, TORRES K E, et al. Adherence to national comprehensive cancer network guidelines is associated with improved survival for patients with stage 2A and stages 2B and 3 extremity and superficial trunk soft tissue sarcoma[J]. Ann Surg Oncol, 2017, 24(11): 3271-3278. doi: 10.1245/s10434-017-6015-z pmid: 28741122
[22]	SCHAEFER I M, HORNICK J L, BARYSAUSKAS C M, et al. Histologic appearance after preoperative radiation therapy for soft tissue sarcoma: assessment of the European organization for research and treatment of cancer-soft tissue and bone sarcoma group response score[J]. Int J Radiat Oncol Biol Phys, 2017, 98(2): 375-383. doi: 10.1016/j.ijrobp.2017.02.087
[23]	TANAKA K, OGAWA G, MIZUSAWA J, et al. Prospective comparison of various radiological response criteria and pathological response to preoperative chemotherapy and survival in operable high-grade soft tissue sarcomas in the Japan Clinical Oncology Group study JCOG0304[J]. World J Surg Oncol, 2018, 16(1): 162. doi: 10.1186/s12957-018-1462-y pmid: 30097070
[24]	WAHL R L, JACENE H, KASAMON Y, et al. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1): 122S-150S. doi: 10.2967/jnumed.108.057307
[25]	YANG X, ZHANG L, YANG X, et al. Oncologic outcomes of pre- versus post-operative radiation in Resectable soft tissue sarcoma: a systematic review and meta-analysis[J]. Radiat Oncol, 2020, 15(1): 158. doi: 10.1186/s13014-020-01600-9 pmid: 32576267
[26]	KALBASI A, KAMRAVA M, CHU F I, et al. A phase Ⅱ trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma[J]. Clin Cancer Res, 2020, 26(8): 1829-1836. doi: 10.1158/1078-0432.CCR-19-3524
[27]	ALBERTSMEIER M, RAUCH A, ROEDER F, et al. External beam radiation therapy for resectable soft tissue sarcoma: A systematic review and meta-analysis[J]. Ann Surg Oncol, 2018, 25(3): 754-767. doi: 10.1245/s10434-017-6081-2 pmid: 28895107

Characteristic	Case
Gender
Male	17 (51.5)
Female	16 (48.5)
Age/year
<60	20 (60.6)
≥60	13 (39.4)
locations of tumor
Head and neck	3 (9.1)
Trunk	11 (33.3)
Upper extremity	3 (9.1)
Lower extremity	15 (45.5)
Retroperitoneum	1 (3.0)
Largest tumor dimension/cm
<5	6 (18.2)
5-10	14 (42.4)
≥10	13 (39.4)
Previous treatments
Primary	13 (39.4)
Recurrence/metastasis
Previous surgery alone	15 (45.5)
Previous chemotherapy alone	1 (3.0)
Previous surgery and chemotherapy	4 (12.1)
Concurrent treatment
Chemotherapy	15 (45.4)
Target therapy	3 (9.1)
Chemotherapy and target therapy	1 (3.0)
Target therapy and immunotherapy	2 (6.1)
No	12 (36.4)

Pathologic subtype	Case
Rhabdomyosarcoma	4 (12.1)
Leiomyosarcoma	1 (3.0)
Fibroblastic and myofibroblastic tumors
Myxofibrosarcoma	3 (9.1)
Others	3 (9.1)
Angiosarcoma	1 (3.0)
Peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumor	1 (3.0)
Malignant triton tumor	1 (3.0)
Others	1 (3.0)
Liposarcoma
Atypical lipomatous tumor/well-differentiated liposarcoma	1 (3.0)
Dedifferentiated liposarcoma	1 (3.0)
Pleomorphic liposarcoma	1 (3.0)
Tumors of uncertain differentiation
Synovial sarcoma	4 (12.1)
epithelioid sarcom	1 (3.0)
Undifferentiated pleomorphic sarcoma	5 (15.2)
Round cell sarcoma
Extraskeletal Ewing’s sarcoma	1 (3.0)
Others	3 (9.1)
Spindle cell sarcoma	1 (3.0)

33例接受术前放疗的局部高危软组织肉瘤患者近期疗效和安全性回顾性分析

Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈如串, 刘伟, 周冰妮, 刘晓航, 周良平. VI-RADS联合肿瘤基底接触长度检测肌层浸润性膀胱癌的价值研究[J]. 中国癌症杂志, 2023, 33(3): 260-266.
[2]	周冰妮, 刘晓航, 顾丙新, 周良平, 顾雅佳. mpMRI联合 ^99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究[J]. 中国癌症杂志, 2022, 32(2): 134-141.
[3]	罗　容, 胡培安, 解添淞, 张泽华, 周良平, 周正荣, 陈　雷 . 黏液纤维肉瘤影像学表现、临床特征及病理学的相关性研究[J]. 中国癌症杂志, 2021, 31(8): 734-739.
[4]	胡冠男, 陈　雷, 周良平, 周正荣 . 肺恶性黑色素瘤合并肺腺癌1例并文献复习[J]. 中国癌症杂志, 2021, 31(7): 647-650.
[5]	董诗洁, 胡晓欣, 王　葳, 杨　孟, 岳　磊, 童　彤, 顾雅佳. 基于多序列MRI与多体系影像组学模型预测子宫颈癌淋巴结转移的研究[J]. 中国癌症杂志, 2021, 31(6): 460-467.
[6]	林瑾仪, 王　妍, 侯惠萍, 周宇红, 刘天舒, 程蕾蕾 . 软组织肉瘤患者可溶性ST2的临床价值：一项单中心横断面研究[J]. 中国癌症杂志, 2020, 30(12): 996-1001.
[7]	孙瑞红,王　翔,沈丽娟,孟凡华,尹化斌 . 乳腺癌患者MRI体素内不相干运动成像中感兴趣区选择方法对参数一致性的影响[J]. 中国癌症杂志, 2019, 29(9): 700-708.
[8]	杨凌舸?,王春萌? . 腺泡状软组织肉瘤药物治疗现状与进展[J]. 中国癌症杂志, 2019, 29(9): 746-752.
[9]	王敏红，周理想，冯湛. 常规MRI纹理分析鉴别脑胶质母细胞瘤和原发性中枢神经系统淋巴瘤的价值[J]. 中国癌症杂志, 2019, 29(4): 284-288.
[10]	顾丙新，孙玉云，杨忠毅，罗建民，张建平，章英剑. ^99mTc-转铁蛋白-DTPA-Gd核素/磁性双模态分子影像探针基于转铁蛋白受体表达水平的肿瘤成像[J]. 中国癌症杂志, 2019, 29(2): 119-124.
[11]	刘梦君，李玉芝，王丽华，常梦然. 鳞状细胞癌抗原检测联合磁共振成像对判断早期宫颈癌盆腔淋巴结转移的临床意义[J]. 中国癌症杂志, 2019, 29(2): 136-141.
[12]	罗春莉　,李志平　 . 软组织肉瘤的分子靶向治疗研究进展[J]. 中国癌症杂志, 2019, 29(10): 824-831.
[13]	沈浩元,胡超华,韩运涛,等. 56例隐匿性乳腺癌临床病理特征分析及诊疗策略探讨[J]. 中国癌症杂志, 2018, 28(6): 429-434.
[14]	张云燕,顾雅佳,吴　斌,等. 头颈部腺样囊性癌的磁共振成像特点[J]. 中国癌症杂志, 2018, 28(5): 347-353.
[15]	徐　晔,周　洋,唐　娜,等. 中段直肠癌术前磁共振成像对术后复发及转移的预测价值研究[J]. 中国癌症杂志, 2018, 28(5): 376-382.